ELTX
Elicio Therapeutics Inc.
NASDAQ: ELTX · HEALTHCARE · BIOTECHNOLOGY
$1.56
-4.29% today
Updated 2026-11-12
Market cap
$43.08M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.16
Dividend yield
—
52W range
$1 – $16
Volume
0.3M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-17.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →259 stocks currently score above 75
Price targets
Analyst target
$13.67
+776.28%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -16.99 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-8.16M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-28.21M | $-35.20M | $-51.90M | $-39.57M | $-8.22M |
| EPS | — | — | — | — | $-2.16 |
| Free cash flow | $-22.83M | $-32.76M | $-37.16M | $-36.97M | $-8.16M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Elicio Therapeutics Inc. trades at $1.56. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -16.99, it sits in the distress.
Frequently asked questions
What is Elicio Therapeutics Inc.'s stock price?
Elicio Therapeutics Inc. (ELTX) trades at $1.56.
Is Elicio Therapeutics Inc. overvalued?
Elicio Therapeutics Inc. carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Elicio Therapeutics Inc. (ELTX)?
The 12-month analyst consensus target is $13.67, about 776.3% above the current $1.56. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Elicio Therapeutics Inc.'s Altman Z-Score is -16.99, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-1,076.00%
Beta2.00
50D MA$2.06
200D MA$6.78
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—